World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 88 1157 1049 101 95 583 31593
Medicine 89 12599 11858 1187 1137 606 32031

Mark T. Drayson publications per year

The chart shows the history of publications by Mark T. Drayson between 1966 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Mark T. Drayson published across 61 years, from 1966 to 2026, averaging 10.9 papers a year. Output peaked at 51 publications in 2023. 14 of the 663 publications appeared in the last two years.

No. of publications
10 20 30 40 50
Bar chart. Horizontal axis: year, 1966 to 2026. Vertical axis: number of publications, 0 to 51. Peak 51 publications in 2023. 1966: 1 publication 1967: 0 publications 1968: 0 publications 1969: 0 publications 1970: 0 publications 1971: 0 publications 1972: 0 publications 1973: 0 publications 1974: 0 publications 1975: 0 publications 1976: 0 publications 1977: 0 publications 1978: 0 publications 1979: 0 publications 1980: 0 publications 1981: 1 publication 1982: 0 publications 1983: 0 publications 1984: 1 publication 1985: 2 publications 1986: 1 publication 1987: 1 publication 1988: 5 publications 1989: 5 publications 1990: 0 publications 1991: 2 publications 1992: 3 publications 1993: 2 publications 1994: 2 publications 1995: 1 publication 1996: 1 publication 1997: 3 publications 1998: 7 publications 1999: 7 publications 2000: 4 publications 2001: 7 publications 2002: 9 publications 2003: 15 publications 2004: 13 publications 2005: 21 publications 2006: 9 publications 2007: 14 publications 2008: 16 publications 2009: 38 publications 2010: 31 publications 2011: 20 publications 2012: 13 publications 2013: 21 publications 2014: 27 publications 2015: 38 publications 2016: 35 publications 2017: 30 publications 2018: 26 publications 2019: 38 publications 2020: 39 publications 2021: 37 publications 2022: 30 publications 2023: 51 publications 2024: 22 publications 2025: 13 publications 2026: 1 publication
1966 2026

663 publications in total across all disciplines

View publications per year as a table
Mark T. Drayson: publications per year, 1966 to 2026
Year Publications
1966 1
1967 0
1968 0
1969 0
1970 0
1971 0
1972 0
1973 0
1974 0
1975 0
1976 0
1977 0
1978 0
1979 0
1980 0
1981 1
1982 0
1983 0
1984 1
1985 2
1986 1
1987 1
1988 5
1989 5
1990 0
1991 2
1992 3
1993 2
1994 2
1995 1
1996 1
1997 3
1998 7
1999 7
2000 4
2001 7
2002 9
2003 15
2004 13
2005 21
2006 9
2007 14
2008 16
2009 38
2010 31
2011 20
2012 13
2013 21
2014 27
2015 38
2016 35
2017 30
2018 26
2019 38
2020 39
2021 37
2022 30
2023 51
2024 22
2025 13
2026 1
Total 663
Download as CSV

Mark T. Drayson publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mark T. Drayson sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 582–591 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 583 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71
392–401 62
402–411 54
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17 583
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

Mark T. Drayson D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark T. Drayson sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 88–89 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 88 D-Index — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184
74–75 133
76–77 163
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96 88
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

Mark T. Drayson is affiliated with the University of Birmingham in the United Kingdom. Their research primarily spans the field of medicine, with significant contributions in hematology, molecular biology, infectious diseases, oncology, and immunology.

The scientist's work covers several focused topics, including:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • SARS-CoV-2 and COVID-19 Research
  • Cancer Treatment and Pharmacology
  • Peptidase Inhibition and Analysis
  • COVID-19 Clinical Research Studies
  • Immunotherapy and Immune Responses

Some of the frequent co-authors with whom Mark T. Drayson has collaborated include:

  • Gordon Cook
  • Roger G. Owen
  • Martin Kaiser
  • Graham Jackson
  • David A. Cairns

The scientist has published in several prominent academic venues, with a strong presence in:

  • Blood
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Lymphoma Myeloma & Leukemia
  • British Journal of Haematology
  • Blood Cancer Journal

Key recent papers authored or co-authored by Mark T. Drayson include:

  • SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study (2020, Thorax)
  • Sensitive Detection of SARS-CoV-2-Specific Antibodies in Dried Blood Spot Samples (2020, Emerging infectious diseases)
  • Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma (2023, Journal of Clinical Oncology)
  • Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials (2020, Blood)
  • Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection (2020, bioRxiv [Cold Spring Harbor Laboratory])

This body of work reflects a focus on infectious diseases, particularly COVID-19, as well as hematological malignancies and their treatment protocols. The contribution to multiple myeloma research is notable with studies addressing both clinical outcomes and pharmacological interventions.

Best Publications

  • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

    Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie

  • High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

    J. Anthony Child;Gareth J. Morgan;Faith E. Davies;Roger G. Owen

  • Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset.

    David A Somerset;Yong Zheng;Mark D Kilby;David M Sansom

  • Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and Urine

    Arthur R. Bradwell;Hugh D. Carr-Smith;Graham P. Mead;Lian X. Tang

  • First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

    Gareth J Morgan;Faith E Davies;Walter M Gregory;Kim Cocks

  • Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

    Brian A. Walker;Eileen M. Boyle;Christopher P. Wardell;Alex Murison

  • Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party

    Bradley M. Augustson;Gulnaz Begum;Janet A. Dunn;Nicola J. Barth

  • Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma

    Mark Drayson;Lian X. Tang;Roger Drew;Graham P. Mead

  • Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.

    C A Bradbury;F L Khanim;R Hayden;C M Bunce

  • Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

    Andy C. Rawstron;J. Anthony Child;Ruth M. de Tute;Faith E. Davies

  • The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

    Gareth J. Morgan;Walter M. Gregory;Faith E. Davies;Sue E. Bell

  • A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

    E. V. McCloskey;I. C. M. Maclennan;M. T. Drayson;C. Chapman

  • Serum test for assessment of patients with Bence Jones myeloma

    Arthur R Bradwell;Hugh D Carr-Smith;Graham P Mead;Timothy C Harvey

  • How I treat monoclonal gammopathy of renal significance (MGRS)

    Jean Paul Fermand;Frank Bridoux;Robert A. Kyle;Efstathios Kastritis

  • Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

    Graham H Jackson;Faith E Davies;Charlotte Pawlyn;Charlotte Pawlyn;David A Cairns

  • APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

    Brian A Walker;Christopher P Wardell;Alex Murison;Eileen M Boyle

  • The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children

    Calman A. MacLennan;Esther N. Gondwe;Chisomo L. Msefula;Robert A. Kingsley

  • Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial

    Joanna E. Long;Mark T. Drayson;Angela E. Taylor;Kai M. Toellner

  • Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

    Andy C. Rawstron;Andy C. Rawstron;Andy C. Rawstron;Faith E. Davies;Faith E. Davies;Faith E. Davies;Ranjit DasGupta;Ranjit DasGupta;Ranjit DasGupta;A. John Ashcroft;A. John Ashcroft;A. John Ashcroft

  • Serum free light chains for monitoring multiple myeloma.

    G. P. Mead;H. D. Carr-Smith;M. T. Drayson;G. J. Morgan

  • SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study.

    Adrian Shields;Adrian Shields;Sian E Faustini;Marisol Perez-Toledo;Sian Jossi

  • Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma

    Brian A Walker;Brian A Walker;Christopher P Wardell;Alexander Murison;Eileen M Boyle

Frequent Co-Authors

Gareth J. Morgan
Gareth J. Morgan Boston University
Faith E. Davies
Faith E. Davies New York University Langone Medical Center
Graham Jackson
Graham Jackson University of Newcastle Australia
Walter M Gregory
Walter M Gregory University of Leeds
Jos A. Bosch
Jos A. Bosch University of Amsterdam
Nigel H. Russell
Nigel H. Russell University of Nottingham
Douglas Carroll
Douglas Carroll University of Birmingham
Christopher Ring
Christopher Ring University of Birmingham
Brian A Walker
Brian A Walker Indiana University – Purdue University Indianapolis
Calman A. MacLennan
Calman A. MacLennan Bill & Melinda Gates Foundation

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in studying Immunology in the USA, exploring related online degree programs can open doors to diverse healthcare careers. Many students transition into advanced nursing roles that complement their immunological knowledge. For example, acnp programs help Family Nurse Practitioners specialize in acute care settings, combining clinical expertise with a deep understanding of immune system responses.

Accelerated options such as the nurse practitioner accelerated program allow students to fast-track their education and enter the healthcare workforce efficiently. These programs are particularly beneficial for those seeking to integrate immunology into patient care roles quickly.

For newcomers to nursing, online pathways like online rn programs for non nurses in florida provide accessible entry points into the profession. These programs offer foundational clinical and scientific knowledge, including elements relevant to immunology.

Additionally, students aiming for a Bachelor of Science in Nursing with a smooth admission process may consider the easiest absn to get into. This pathway supports rapid advancement while building expertise that can intersect with immunological research and practice.

Best Scientists Citing Mark T. Drayson

Trending Scientists

Recently Published Articles